Jump to content

ITI-1549

Add links
From Wikipedia, the free encyclopedia
(Redirected from ITI1549)

ITI-1549
Clinical data
Other namesITI1549
Routes of
administration		Oral[1]
Drug classNon-hallucinogenic serotonin 5-HT2A receptor agonist and 5-HT2B receptor antagonist[2][3]

ITI-1549 is a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist as well as serotonin 5-HT2B receptor antagonist which is under development for the treatment of mood disorders and other psychiatric disorders.[1][4][5][2][3] Its route of administration has not been specified.[1]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Serotonergic psychedelics like psilocybin and lysergic acid diethylamide (LSD) are agonists of the serotonin 5-HT2A receptor which activate both the β-arrestin and Gq signaling pathways.[3] In 2023, activation of the Gq pathway, but not the β-arrestin pathway, was linked with the production hallucinogenic-like effects in animals.[3][6][7][8] However, findings in this area are seemingly conflicting, with Gq-selective serotonin 5-HT2A receptor agonists also reported to be non-hallucinogenic.[9] Serotonin 5-HT2A receptor agonists are of interest for the potential treatment of psychiatric disorders like depression and anxiety, but the hallucinogenic effects of serotonergic psychedelics serve as a barrier and partial limiting factor in this regard.[10][11]

ITI-1549 has high affinity for the serotonin 5-HT2A receptor (Ki = 10.2 nM) and acts as a partial agonist of the β-arrestin pathway with an intrinsic activity of 72% (relative to α-methylserotonin).[3] Conversely, unlike serotonergic psychedelics, ITI-1549 does not activate the Gq pathway.[3] Hence, it is a biased agonist of the serotonin 5-HT2A receptor.[3] In accordance with the preceding, ITI-1549 does not produce the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in animals.[3][12][13] However, similarly to serotonergic psychedelics, ITI-1549 has been found to produce anxiolytic-like and prosocial effects in animals.[3] Antidepressant-like and pro-synaptogenic effects of ITI-1549 in animals have yet to be assessed or reported.[3] In any case, various other non-hallucinogenic serotonin 5-HT2A receptor agonists selective for the β-arrestin pathway have been found to produce antidepressant-like effects in animals.[7][10][14]

In addition to the serotonin 5-HT2A receptor, ITI-1549 has high affinity for the serotonin 5-HT2B receptor (Ki = 4.8 nM).[3] However, it acts as an antagonist of this receptor rather than as an agonist (IC50Tooltip half-maximal inhibitory concentration = 13.8 nM).[3] Based on these findings, continuous administration of ITI-1549 is not expected to pose a risk of cardiac valvulopathy.[3] This is in contrast to serotonergic psychedelics, which act as potent serotonin 5-HT2B receptor agonists.[15][16]

Chemistry

[edit]

The drug is a small molecule, but its chemical structure does not yet seem to have been disclosed.[1][4] It is said to be chemically unrelated to existing plant-derived and synthetic serotonergic psychedelics.[3] However, its structure was disclosed in a 2024 patent.[17]

Clinical trials

[edit]

As of February 2024, ITI-1549 is in the preclinical stage of development for psychiatric disorders.[1][4][2] It is under development by Intra-Cellular Therapies.[1][4][2] ITI-1549 was first described in the scientific literature by 2023.[3]

See also

[edit]

References

[edit]
  1. ^ a b c d e f "ITI 1549". AdisInsight. 15 January 2024. Retrieved 23 October 2024.
  2. ^ a b c d Intra-Cellular Therapies (22 February 2024). "Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update". GlobeNewswire News Room. Retrieved 23 October 2024. ITI-1500 Non-Hallucinogenic Psychedelic Program: In 2023, we introduced the ITI-1500 program. This program is focused on the development of novel non-hallucinogenic psychedelics for the treatment of mood, anxiety and other neuropsychiatric disorders without the liabilities of known psychedelics, including the hallucinogenic potential and risk for cardiac valvular pathologies. Our lead product candidate in this program, ITI-1549, is advancing through IND enabling studies and is expected to enter human testing in late 2024 or early 2025.
  3. ^ a b c d e f g h i j k l m n o "ACNP 62nd Annual Meeting: Poster Abstracts P251 - P500". Neuropsychopharmacology. 48 (Suppl 1): 211–354. December 2023. doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.
  4. ^ a b c d "Delving into the Latest Updates on ITI-1549 with Synapse". Synapse. 12 October 2024. Retrieved 23 October 2024.
  5. ^ "Pipeline". Intracellular Therapies. Retrieved 23 October 2024. Pipeline: [...] ITI-1500 Series: ITI-1549 – Mood and Other Neuropsychiatric Disorders [...] ITI-1500 series is our portfolio of Non-Hallucinogenic Psychedelics. ITI-1549 is our lead product candidate in this program.
  6. ^ Glennon RA, Dukat M (June 2024). "1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review". ACS Pharmacology & Translational Science. 7 (6): 1722–1745. doi:10.1021/acsptsci.4c00157. PMID 38898956. Although the specific signaling cascades mediating the HTR have not been conclusively identified, Gq and β-arrestin2 have been implicated. Recent studies with different existing and novel agents, including DOI, found that the HTR was correlated with Gq efficacy but not with β-arrestin2 recruitment.114
  7. ^ a b Chisamore N, Kaczmarek E, Le GH, Wong S, Orsini DK, Mansur R, et al. (26 April 2024). "Neurobiology of the Antidepressant Effects of Serotonergic Psychedelics: A Narrative Review". Current Treatment Options in Psychiatry. 11 (2). Springer Science and Business Media LLC: 90–105. doi:10.1007/s40501-024-00319-8. ISSN 2196-3061.
  8. ^ Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, et al. (July 2023). "Identification of 5-HT2A Receptor Signaling Pathways Responsible for Psychedelic Potential". bioRxiv. doi:10.1101/2023.07.29.551106. PMC 10418054. PMID 37577474.
  9. ^ Schmitz GP, Roth BL (July 2023). "G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics". American Journal of Physiology. Cell Physiology. 325 (1): C17–C28. doi:10.1152/ajpcell.00397.2022. PMC 10281788. PMID 37067459.
  10. ^ a b Duan W, Cao D, Wang S, Cheng J (January 2024). "Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants". Chemical Reviews. 124 (1): 124–163. doi:10.1021/acs.chemrev.3c00375. PMID 38033123.
  11. ^ Atiq MA, Baker MR, Voort JL, Vargas MV, Choi DS (May 2024). "Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties". Psychopharmacology. doi:10.1007/s00213-024-06599-5. PMID 38743110.
  12. ^ Canal CE, Morgan D (2012). "Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model". Drug Testing and Analysis. 4 (7–8): 556–576. doi:10.1002/dta.1333. PMC 3722587. PMID 22517680.
  13. ^ Kozlenkov A, González-Maeso J (2013). "Animal Models and Hallucinogenic Drugs". The Neuroscience of Hallucinations. New York, NY: Springer New York. p. 253–277. doi:10.1007/978-1-4614-4121-2_14. ISBN 978-1-4614-4120-5.
  14. ^ Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. (January 2022). "Structure-based discovery of nonhallucinogenic psychedelic analogs". Science. 375 (6579): 403–411. doi:10.1126/science.abl8615. PMID 35084960.
  15. ^ Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R (September 2023). "The risk of chronic psychedelic and MDMA microdosing for valvular heart disease". Journal of Psychopharmacology. 37 (9): 876–890. doi:10.1177/02698811231190865. PMID 37572027.
  16. ^ Rouaud A, Calder AE, Hasler G (March 2024). "Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins". Journal of Psychopharmacology. 38 (3): 217–224. doi:10.1177/02698811231225609. PMC 10944580. PMID 38214279.
  17. ^ Intra-Cellular Therapies (29 December 2023). "Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor". Google Patents. Retrieved 23 October 2024. Examples 1 to 180 are, or will be, synthesized and characterized: [...] Ex.: 40. X: -N(CH3)-. Y: -CH2-. m: 1. n: 2. Z: bond. A: benzo[d]isoxazol-3-yl [...] Examples 24, 25, and 40, also show zero G-q mediated agonist activity, but while the compound of Example 24 is a beta-arrestin antagonist, the compounds of Examples 25 and 40 are beta-arrestin partial agonists. [...] The following receptor affinity results are obtained (with the Compound of Formula A for comparison): [...] Ex.: 40. 5-HT2A (%): 87%. 5-HT2A Ki: 10. [...] Selected compounds are also tested in receptor binding assays for the 5-HT2B, and/or 5-HT2C receptors. Some results are shown in the following table: Ex.: 40. 5-HT2A (%): 87%. 5-HT2A Ki: 10. 5-HT2B (%): 80%. 5-HT2B Ki: 4.8. 5-HT2C (%): 81%. 5-HT2C Ki: 21.
Retrieved from "https://en.wikipedia.org/w/index.php?title=ITI-1549&oldid=1252882180"